Comparison · NCT00520286-13027418
Modafinil vs Placebo: Reduction of Craving
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Modafinil vs Placebo: Reduction of Craving. Trial comparisons, record NCT00520286-13027418. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00520286-13027418
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.225 | 0.164 | 0.301 | wilson | |
| Risk in group 2 | 0.147 | 0.0819 | 0.25 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0783 | -0.0413 | 0.178 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.53 | 0.801 | 2.93 | log | |
| Odds ratio, group 1 over group 2 | 1.69 | 0.775 | 3.67 | log | |
| Number needed to treat, for one more participant with the outcome on Modafinil than on Placebo | 12.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Modafinil | Participants will receive a Modafinil 200 mg or 400 mg tablet one time per day for 12 weeks~Modafinil: 200 mg or 400 mg /daily | 32 | 142 | OG000 |
| Group 2 | Placebo | Participants will receive a matching Modafinil placebo 200 mg or 400 mg tablet one time per day for 12 weeks~Placebo: Placebo / daily | 10 | 68 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Reduction of Craving
- Description
- Number of subjects with 21 or more consecutive days of abstinence
- Time frame
- 21 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
- NCT number
- NCT00520286
- Phases
- PHASE2
- Conditions
- Methamphetamine Dependence
- Interventions
- Modafinil, Placebo
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- Results first posted
- 2017-04-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00520286?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00520286-13027418